Physician profile
Hammad A Qureshi
NPI 1205123528
$4,685.75
in general payments reported to CMS, 2019-2025
37 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $359 · 2021: $615 · 2022: $556 · 2023: $524 · 2024: $832 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,886.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,019.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $576.53 | 2023-2025 | Inspire |
| Insmed, INC. | $379.79 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $344.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Electromed, INC. | $334.31 | 2019-2021 | |
| Lilly USA, LLC | $287.16 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $264.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Antares Pharma, INC. | $129.41 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Genzyme Corporation | $116.10 | 2024 | |
| Pulmonx Corporation | $97.62 | 2020 | |
| Amgen INC. | $87.41 | 2022-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.01 | 2024-2025 | Xifaxan |
| Abbott Laboratories | $78.41 | 2022-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $75.38 | 2020-2024 | Spravato |
| Boston Scientific Corporation | $75.03 | 2022-2023 | Watchman Access System |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.